Bone metastases from gynaecological epithelial cancers

• Published in: Journal of obstetrics and gynaecology Vol. 32; no. 1; pp. 81 - 86
• Main Authors: Gottwald, L., Dukowicz, A., Piekarski, J., Misiewicz, B., Spych, M., Misiewicz, P., Kazmierczak-Lukaszewicz, S., Moszynska-Zielinska, M., Cialkowska-Rysz, A.
• Format: Journal Article
• Language: English
• Published: England Informa Healthcare 01-01-2012; Taylor & Francis; Taylor & Francis Ltd
• Subjects: Adenocarcinoma - mortality; Adenocarcinoma - secondary; Adult; Aged; Bone metastases; Bone Neoplasms - mortality; Bone Neoplasms - secondary; Bones; Cancer; Carcinoma, Squamous Cell - mortality; Carcinoma, Squamous Cell - secondary; diagnostics; Female; Genital Neoplasms, Female - mortality; Genital Neoplasms, Female - pathology; gynaecological cancers; Gynecology; Humans; Medical diagnosis; Medical treatment; Metastasis; Middle Aged; Poland - epidemiology; Retrospective Studies; survival treatment; Poland
• ISSN: 0144-3615; 1364-6893
• DOI: 10.3109/01443615.2011.619672

The aim of this study was to investigate the clinical features and prognosis in patients with gynaecological epithelial cancers metastasised to bones. A total of 26 patients were studied retrospectively. Clinical and pathological data were analysed along with a follow-up. It was found that the interval from primary diagnosis of cancer until bony relapse varied between 0 and 163 months (31.4 ± 36.8). Bone metastases were solitary in 11 cases and multifocal in 15 cases. A total of 14 patients demonstrated only bony metastases while 12 had both bony and non-bony metastases. The time to follow-up from the diagnosis of osseous relapse varied between 1 and 43 months (10.0 ± 10.4). During follow-ups, 13 patients died and 13 patients survived. In both univariate and multivariate analyses, synchronous non-bony metastases and symptomatic treatment without oncological therapy impaired prognosis. It was concluded that even in the presence of multiple bone metastases, some patients may benefit from radiotherapy, chemotherapy or a combination of both, rather than palliative care alone, providing they do not have additional soft tissue metastases.